Abivax S.A.
ABVX
NASDAQ·Healthcare·Biotechnology·Mkt cap $8.4B
$113.00
▼ -0.91%
P/E
-14.17
Mkt Cap
$8.4B
52-Wk Range
$69.81–$148.83
52-Week Range
$69.81 - $148.83
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 33.3% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
No bull reasons captured for this rating yet.
Bear Case
1 risk
- Low volatility (beta -0.2).
Growth
Revenue decline expected
Value
Deep value opportunity - significant discount to sector peers
Momentum
Strong
+8.7% over 3m
Quality
Loss-making
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying ABVX right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Sep 21, 2026
Most recent quarter reported revenue of $-2.4M (-127% YoY). Reported EPS of -$3.59.
Reported EPS · last 4Q
Q4 25
-$3.59
Q2 25
-$1.86
Q4 24
-$1.76
Q2 24
-$0.76
Revenue trend · last 8Q
—
—
+1%
+3%
+51%
+218%
-41%
-127%
Q2 22
Q4 22
Q2 23
Q4 23
Q2 24
Q4 24
Q2 25
Q4 25
$2.6M
$2.6M
$2.6M
$2.7M
$4.0M
$8.7M
$2.4M
-$2.4M
Margins · last 8Q
Gross
—
Profit
—
Wall Street consensus
8 analysts · 88% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
88%
Hold
13%
Sell
0%
Median Price Target
—
Latest: Morgan Stanley · Jul 24, 2026
vs Industry
How ABVX stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.